AU2013355110B2 - Beta-lactamase inhibitors - Google Patents

Beta-lactamase inhibitors Download PDF

Info

Publication number
AU2013355110B2
AU2013355110B2 AU2013355110A AU2013355110A AU2013355110B2 AU 2013355110 B2 AU2013355110 B2 AU 2013355110B2 AU 2013355110 A AU2013355110 A AU 2013355110A AU 2013355110 A AU2013355110 A AU 2013355110A AU 2013355110 B2 AU2013355110 B2 AU 2013355110B2
Authority
AU
Australia
Prior art keywords
cr6r7
nr4r5
vnr4r5
compound
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013355110A
Other languages
English (en)
Other versions
AU2013355110A1 (en
Inventor
Christopher J. Burns
Denis Daigle
Bin Liu
Daniel Mcgarry
Daniel C. Pevear
Robert E. Lee TROUT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VenatoRx Pharmaceuticals Inc
Original Assignee
VenatoRx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VenatoRx Pharmaceuticals Inc filed Critical VenatoRx Pharmaceuticals Inc
Publication of AU2013355110A1 publication Critical patent/AU2013355110A1/en
Application granted granted Critical
Publication of AU2013355110B2 publication Critical patent/AU2013355110B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AU2013355110A 2012-12-07 2013-12-05 Beta-lactamase inhibitors Active AU2013355110B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734900P 2012-12-07 2012-12-07
US61/734,900 2012-12-07
US201361783238P 2013-03-14 2013-03-14
US61/783,238 2013-03-14
PCT/US2013/073428 WO2014089365A1 (en) 2012-12-07 2013-12-05 Beta-lactamase inhibitors

Publications (2)

Publication Number Publication Date
AU2013355110A1 AU2013355110A1 (en) 2015-07-02
AU2013355110B2 true AU2013355110B2 (en) 2017-11-09

Family

ID=50884012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013355110A Active AU2013355110B2 (en) 2012-12-07 2013-12-05 Beta-lactamase inhibitors

Country Status (16)

Country Link
US (6) US9422314B2 (cg-RX-API-DMAC7.html)
EP (2) EP2928898B1 (cg-RX-API-DMAC7.html)
JP (2) JP6403219B2 (cg-RX-API-DMAC7.html)
KR (1) KR102147420B1 (cg-RX-API-DMAC7.html)
CN (1) CN105026407B (cg-RX-API-DMAC7.html)
AU (1) AU2013355110B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015013123B1 (cg-RX-API-DMAC7.html)
CA (1) CA2893943C (cg-RX-API-DMAC7.html)
ES (1) ES2878118T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210879T1 (cg-RX-API-DMAC7.html)
IL (1) IL239212B (cg-RX-API-DMAC7.html)
PL (1) PL2928898T3 (cg-RX-API-DMAC7.html)
PT (1) PT2928898T (cg-RX-API-DMAC7.html)
RU (1) RU2654692C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014089365A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201504200B (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE048859T2 (hu) 2010-08-10 2020-08-28 Rempex Pharmaceuticals Inc Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
RU2654692C2 (ru) * 2012-12-07 2018-05-22 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамаз
EA201591003A1 (ru) * 2013-01-04 2015-12-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
AU2014204046B2 (en) 2013-01-04 2017-02-23 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
PT3140310T (pt) 2014-05-05 2019-11-18 Rempex Pharmaceuticals Inc Síntese de sais de boronato e utilizações dos mesmos
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112016026291A2 (pt) 2014-05-19 2017-08-15 Rempex Pharmaceuticals Inc Derivados do ácido borônico e usos terapêuticos dos mesmos
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2950917C (en) 2014-06-11 2022-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
MX2016016666A (es) * 2014-07-01 2017-08-08 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016100043A1 (en) * 2014-12-19 2016-06-23 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
CA2971763A1 (en) * 2014-12-23 2016-06-30 Bergenbio Asa Inhibitors of akt kinase
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10399996B2 (en) 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
SG11201811549UA (en) 2016-06-30 2019-01-30 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
GB201613946D0 (en) * 2016-08-15 2016-09-28 Univ Oslo Compounds
CN110678186A (zh) * 2017-03-06 2020-01-10 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
TW201841642A (zh) * 2017-04-28 2018-12-01 日商大日本住友製藥股份有限公司 雜環衍生物
GB201708002D0 (en) 2017-05-18 2017-07-05 Univ Oxford Innovation Ltd ß-Lactamase inhibitors
CN110959008A (zh) * 2017-05-26 2020-04-03 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN111212843B (zh) 2017-10-11 2025-05-16 Qpex生物制药有限公司 硼酸衍生物及其合成
JOP20200101A1 (ar) * 2017-11-01 2022-10-30 Melinta Therapeutics Inc تخليق مشتقات إستر بورونات واستخداماتها
JP7329260B2 (ja) 2018-04-20 2023-08-18 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
WO2019208797A1 (ja) 2018-04-27 2019-10-31 大日本住友製薬株式会社 オキソ置換化合物
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2020056048A1 (en) 2018-09-12 2020-03-19 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
WO2020205932A1 (en) * 2019-04-02 2020-10-08 VenatoRx Pharmaceuticals, Inc. Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof
JP7654554B2 (ja) 2019-10-25 2025-04-01 住友ファーマ株式会社 新規置換縮環型化合物
JP7550421B2 (ja) * 2019-10-25 2024-09-13 住友ファーマ株式会社 オキソ置換化合物からなる医薬
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
WO2021108023A1 (en) 2019-11-26 2021-06-03 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP4201942A4 (en) * 2020-08-20 2024-08-21 Phaeno Therapeutics Co., Ltd. BORACIC ACID COMPOUND
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US20250340577A1 (en) * 2021-03-02 2025-11-06 Case Western Reserve University Beta-lactomase inhibitors and uses thereof
US20240209004A1 (en) * 2021-04-13 2024-06-27 Tuojie Biotech (Shanghai) Co., Ltd. BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITOR
CN119384424A (zh) * 2022-02-18 2025-01-28 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
WO2010056827A1 (en) * 2008-11-13 2010-05-20 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE41109B1 (en) 1974-04-20 1979-10-24 Beecham Group Ltd Novel -lactam antibiotic from streptomyces clavuligerus
IT1283467B1 (it) * 1996-07-19 1998-04-21 Menarini Farma Ind Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni
JP2003509428A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
JP2007505950A (ja) * 2003-06-10 2007-03-15 フルクラム・ファーマシューティカルズ・インコーポレーテッド β−ラクタマーゼ阻害剤およびその使用方法
DK1756121T3 (da) 2004-03-30 2012-01-09 Millennium Pharm Inc Syntese af borester- og borsyreforbindelser
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
CN103724330B (zh) 2005-12-07 2015-08-19 巴斯利尔药物股份公司 单环-内酰胺类抗生素与β-内酰胺酶抑制剂的有效的联合应用
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
MX2010005252A (es) * 2007-11-13 2011-04-11 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa.
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
HUE048859T2 (hu) 2010-08-10 2020-08-28 Rempex Pharmaceuticals Inc Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk
BR112013032770A2 (pt) 2011-07-26 2017-02-07 Wockhardt Ltd composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase
CA2847336C (en) 2011-09-04 2021-09-07 Glytech, Inc. Glycosylated polypeptide and drug composition containing said polypeptide
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
JP6129203B2 (ja) 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
BR112015012909A2 (pt) 2012-12-03 2017-07-11 Hoffmann La Roche compostos de ácido borônico de triazol substituído
RU2654692C2 (ru) 2012-12-07 2018-05-22 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамаз
AU2014204046B2 (en) 2013-01-04 2017-02-23 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201591003A1 (ru) 2013-01-04 2015-12-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en) * 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
BR112016026291A2 (pt) 2014-05-19 2017-08-15 Rempex Pharmaceuticals Inc Derivados do ácido borônico e usos terapêuticos dos mesmos
CA2950917C (en) 2014-06-11 2022-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US20150361107A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016035846A1 (ja) 2014-09-04 2016-03-10 塩野義製薬株式会社 カテコール基を有するセファロスポリン類を含有する製剤
WO2016100043A1 (en) 2014-12-19 2016-06-23 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
US10399996B2 (en) 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
CN110678186A (zh) 2017-03-06 2020-01-10 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN110959008A (zh) 2017-05-26 2020-04-03 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
US11247965B2 (en) 2017-12-11 2022-02-15 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
WO2010056827A1 (en) * 2008-11-13 2010-05-20 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OLIV EIDAM ET AL., "Design, synthesis, crystal structures and antimicrobial activity of sulfonamide boronic acids as beta-lactamase inhibitors", J MED CHEM., (20101111), vol. 53, no. 21, pages 7852 - 7863 *

Also Published As

Publication number Publication date
US9828391B2 (en) 2017-11-28
IL239212B (en) 2019-10-31
BR112015013123B1 (pt) 2021-02-17
RU2654692C2 (ru) 2018-05-22
JP2018184409A (ja) 2018-11-22
CN105026407A (zh) 2015-11-04
US20250236632A1 (en) 2025-07-24
WO2014089365A1 (en) 2014-06-12
CA2893943A1 (en) 2014-06-12
BR112015013123A2 (pt) 2017-07-11
US20160326189A1 (en) 2016-11-10
CN105026407B (zh) 2017-09-08
US20150291630A1 (en) 2015-10-15
AU2013355110A1 (en) 2015-07-02
PL2928898T3 (pl) 2021-10-25
IL239212A0 (en) 2015-07-30
ZA201504200B (en) 2017-09-27
HK1217334A1 (zh) 2017-01-06
US20140171390A1 (en) 2014-06-19
EP2928898A4 (en) 2016-06-29
US8912169B2 (en) 2014-12-16
US20180194783A1 (en) 2018-07-12
JP6403219B2 (ja) 2018-10-10
US9422314B2 (en) 2016-08-23
HRP20210879T1 (hr) 2021-08-20
ES2878118T3 (es) 2021-11-18
KR102147420B1 (ko) 2020-08-25
KR20150109348A (ko) 2015-10-01
RU2015126912A (ru) 2017-01-12
US20190225628A1 (en) 2019-07-25
US10214547B2 (en) 2019-02-26
US10669290B2 (en) 2020-06-02
PT2928898T (pt) 2021-07-05
JP2016502973A (ja) 2016-02-01
EP2928898B1 (en) 2021-04-14
EP2928898A1 (en) 2015-10-14
CA2893943C (en) 2021-03-02
EP3922635A1 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
AU2013355110B2 (en) Beta-lactamase inhibitors
US11414435B2 (en) Beta-lactamase inhibitors
EP2970340B1 (en) Beta-lactamase inhibitors
EP3882252B1 (en) Beta-lactamase inhibitors
HK1217334B (en) Beta-lactamase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)